AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14645935
Drug: Combined patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined patch groups (active + placebo)
Trial: 10537958
Drug: Continuous intrathecal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrathecal baclofen infusion
Trial: 31059495
Drug: Biannual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual mass drug administration (MDA) with praziquantel alone
Trial: 25035603
Drug: Yoga group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga group (with standard medical treatment and yogic intervention)
Trial: 25035603
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard medical treatment without yogic intervention)
Trial: 22181063
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (iGlar) with regular insulin (iReg)
Trial: 12764986
Drug: Live Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Lactobacillus plantarum 299 (10^9 live bacteria) with oat fibre substrate, administered twice daily for 7 days.
Trial: 12764986
Drug: Heat-killed Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed Lactobacillus plantarum 299, administered twice daily for 7 days.
Trial: 12764986
Drug: Live Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Lactobacillus plantarum 299 (treatment group)
Trial: 10021717
Drug: Prophylaxis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis with 200 mg/kg of porcine surfactant
Trial: 8418402
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment and selective ERCP with or without endoscopic papillotomy
Trial: 31315446
Drug: Monthly telemedical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly telemedical consultations in addition to regular care
Trial: 29573247
Drug: Quadrivalent Influenza
RxNorm normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent Influenza Vaccine (GC3110A)
Trial: 29573247
Drug: Trivalent Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent Influenza Vaccine (Control)
Trial: 21596578
Drug: Bupivacaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (1.5 mg kg(‐1) via paravertebral subpleural catheter for 3 days)
Trial: 21596578
Drug: Morphine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.2 mg kg(‐1) via paravertebral subpleural catheter for 3 days)
Trial: 21596578
Drug: Control (tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (tramadol 100 mg plus metamizol 1000 mg intravenously every 4 h for 3 days)
Trial: 20438942
Drug: Chemotherapy +/-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy +/- radiation therapy or surgery alone (historical controls)
Trial: 30878487
Drug: rAAV.sFLT-1 gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV.sFLT-1 gene therapy (GT)
Trial: 27567022
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave treatment (rESWT) - two sessions, 2,000 shock waves per session, energy flux density of 0.16 mJ/mm2
Trial: 27567022
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave treatment (rESWT)
Trial: 26639151
Drug: Leaf concentrate
RxNorm normalized name: Belladonna Leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaf concentrate powder (LCP) 10 g daily
Trial: 26639151
Drug: Skimmed milk
RxNorm normalized name: Calcium fortified skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skimmed milk powder (SMP) 15 g daily
Trial: 18952469
Drug: Face-to-face treatments
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face treatments
Trial: 15327047
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) 24 mg/day
Trial: 15327047
Drug: fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluoxetine (FLX) 20 mg/day
Trial: 11346221
Drug: Meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg daily for 4 weeks
Trial: 11346221
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg daily for 4 weeks
Trial: 8431908
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with extended field radiation
Trial: 3631918
Drug: Scopolamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.25 mg)
Trial: 22468766
Drug: Fructose +
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose + maltodextrin solution
Trial: 22468766
Drug: Fructose +
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose + maltodextrin solution (adjusted for gastrointestinal discomfort)
Trial: 16248240
Drug: Diane-35 in
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane-35 in the Western medicine group (WMG)
Trial: 16248240
Drug: Conventional controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional controlled medicine plus modified Yougui Pill in the integrative medicine group (IMG)
Trial: 9607357
Drug: Adriamycine, vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycine, vincristine (AV) alternated with CMF, then radiotherapy, followed by four cycles of chemotherapy (AV/CMF); and tamoxifen during the entire treatment period (arm III)
Trial: 7617803
Drug: Nicotine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (20 micrograms/kg) administered 30 min before challenge
Trial: 7617803
Drug: Nicotine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (20 micrograms/kg) administered 60 min before challenge
Trial: 7617803
Drug: Nicotine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (20 micrograms/kg) administered 120 min before challenge
Trial: 7617803
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 30 min before challenge
Trial: 65196
Drug: Candicidin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candicidin (300 mg daily dose, 6 capsules per day)
Trial: 23828184
Drug: Combined massage-exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined massage-exercise therapy
Trial: 21216512
Drug: Topical polyantibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical polyantibiotic ointment application at CVC exit sites (1 time/week)
Trial: 21216512
Drug: Topical polyantibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical polyantibiotic ointment application at CVC exit sites
Trial: 18989889
Drug: Paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel at 250 mg/m2
Trial: 18989889
Drug: Paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel at 325 mg/m2
Trial: 18989889
Drug: Paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel at 425 mg/m2
Trial: 18989889
Drug: Paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel at 550 mg/m2
Trial: 18989889
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paclitaxel and ifosfamide
Trial: 15282382
Drug: Asthma medication
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asthma medication usage
Trial: 11347287
Drug: Chlorella supplementation
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella supplementation (10 g in tablet form and 100 mL liquid extract daily for 2 or 3 months)
Trial: 3693583
Drug: Long-acting propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol 160 mg/d
Trial: 3693583
Drug: Conventional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol 40 mg qid
Trial: 28377360
Drug: Shangbai ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shangbai ointment treatment
Trial: 24092872
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg, 1 dose)
Trial: 17339866
Drug: Short-acting inhaler
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting inhaler beta2 mimetic as required + 800 mug inhaler budesonide + leukotriene receptor antagonist
Trial: 2658142
Drug: Mifepristone 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 400 mg/d
Trial: 1103724
Drug: Variable Dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable Dosage Regimen (VDR)
Trial: 22436099
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nifedipine with 480 mg of curcuminoid (6 tablets of turmeric extract)
Trial: 22436099
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nifedipine (control)
Trial: 9013080
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (control group)
Trial: 1521049
Drug: Cigarette yield,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette yield, consumption, self-reported inhalation, and puffing characteristics under standardized smoking conditions (30 puffs through a holder)
Trial: 1521049
Drug: Cigarette yield,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette yield, consumption, self-reported inhalation, and puffing characteristics under natural smoking conditions
Trial: 1521049
Drug: Cigarette yield,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette yield, consumption, self-reported inhalation, and puffing characteristics
Trial: 2146242
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g spectinomycin
Trial: 3156805
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ceftriaxone
Trial: 30035423
Drug: Speroton complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speroton complex with general therapy
Trial: 30035423
Drug: General therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General therapy (Control Group)
Trial: 27484782
Drug: LED-RL phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LED-RL phototherapy at doses of 160 J/cm², 320 J/cm², 480 J/cm², and 640 J/cm²
Trial: 25236915
Drug: Vilazodone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone (5 mg) with ketoconazole (200 mg once daily)
Trial: 25236915
Drug: Vilazodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone (10 mg) with ketoconazole (200 mg once daily)
Trial: 25236915
Drug: Vilazodone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone (40 mg once daily) with carbamazepine (steady-state)
Trial: 15206537
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with bisphosphonates
Trial: 9389897
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (Mg(OH)2; 411-548 mg Mg/d)
Trial: 8198658
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous loading dose of phenytoin
Trial: 8198658
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral phenytoin supplementation
Trial: 8198658
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous loading dose of phenytoin (entire group analysis)
Trial: 27542303
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 μg/kg per h, from ICU admission on the day of surgery until 0800 h on postoperative day 1)
Trial: 27542303
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 μg/kg per h)
Trial: 18715160
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by standard single dose of PPV23 (unprimed group)
Trial: 12679174
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d plant stanol (3.4 g of stanol ester)
Trial: 12679174
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d plant stanol (5.1 g of stanol ester)
Trial: 11122545
Drug: Early triage
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early triage angiography and subsequent therapies based on the angiogram
Trial: 9169300
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 +/- 2.5 mg/day, 10 +/- 2.5 mg/day, 15 +/- 2.5 mg/day)
Trial: 1383071
Drug: rIFN-alpha therapy
RxNorm normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-alpha therapy
Trial: 29532078
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (TODAY)
Trial: 27002003
Drug: Morphine Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine Group (10 mg bupivacaine 0.5% and 0.5 mg morphine)
Trial: 27002003
Drug: Morphine-Dex Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-Dex Group (10 mg bupivacaine 0.5%, 0.5 mg morphine and 5 µg dexmedetomidine)
Trial: 27002003
Drug: Bupivacaine Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine Group (10 mg bupivacaine 0.5%)
Trial: 25298196
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to group therapy
Trial: 25298196
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to individual web-based tobacco treatment
Trial: 20357370
Drug: Metformin (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (425 mg/day for younger girls and 850 mg/day for older girls)
Trial: 19338489
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (1 g twice daily) in combination with cyclosporine and steroids (impaired group)
Trial: 15793608
Drug: Aggressive LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive LDL-C lowering (high-dose lovastatin therapy)
Trial: 15793608
Drug: Moderate LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate LDL-C lowering (low-dose lovastatin therapy)
Trial: 10088567
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin at 0.043 U/kg per hour
Trial: 10088567
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous insulin administration
Trial: 1823632
Drug: Melatonin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin therapy (5 mg/m2/day to 700 mg/m2/day in four divided doses)
Trial: 1823632
Drug: Melatonin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin therapy
Trial: 6367857
Drug: L-PAM (L-phenylalanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PAM (L-phenylalanine mustard) for 2 years
Trial: 27075913
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid 600 μg/d
Trial: 22591408
Drug: Neurosurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurosurgical treatment for SAH
Trial: 20349685
Drug: Sertaconazole nitrate
RxNorm normalized name: Sertaconazole Nitrate
DrugBank: Sertaconazole (DB01153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertaconazole nitrate cream 2%
Trial: 16452557
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (blood glucose levels normalized to 80 to 110 mg/dL using insulin infusion)
Trial: 16452557
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (for patients staying in ICU for three or more days)
Trial: 16452557
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (insulin administered when blood glucose exceeded 215 mg/dL)
Trial: 11232529
Drug: Capozide-50 (C-50)
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capozide-50 (C-50) + melatonin (3 mg at 10.00 p.m.)
Trial: 8737131
Drug: Sparfloxacin 200
RxNorm normalized name: sparfloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 200 mg
Trial: 18093254
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg kg(‐1) pyrazinamide
Trial: 18093254
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg kg(‐1) pyrazinamide
Trial: 12589392
Drug: Delta(9)-THC (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta(9)-THC (up to 10 mg)
Trial: 8615355
Drug: all-rac-alpha-tocopheryl acetate
RxNorm normalized name: all-rac-alpha-tocopheryl acetate
DrugBank: DL-alpha tocopheryl acetate (DB14477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all-rac-alpha-tocopheryl acetate (400 mg, n = 10)
Trial: 8615355
Drug: water-miscible preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water-miscible preparation (400 mg, n = 9)
Trial: 8615355
Drug: All preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All preparations (A, B, C)
Trial: 6425911
Drug: Combined thioridazine
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined thioridazine (100 mg THI/day for the first 7 days) and desipramine (200 mg DMI/day for 21 days)
Trial: 6425911
Drug: Desipramine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (200 mg DMI/day for 21 days)
Trial: 23978222
Drug: Midodrine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (2.5 to 10 mg three times daily for 2 weeks)
Trial: 22325733
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 6000 mg
Trial: 19085624
Drug: Single-dose maternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose maternal methadone administration
Trial: 19085624
Drug: Split-dose maternal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose maternal methadone administration
Trial: 17466338
Drug: Subcutaneous apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous apomorphine (APO) 4 mg
Trial: 11291581
Drug: Experimental treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatments from the Health Education and Research Trial (HEART) Project
Trial: 8390768
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of alpha lipoic acid daily for 3 months
Trial: 8390768
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of selenium (sodium selenite) daily for 3 months
Trial: 8390768
Drug: 1200 IE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 IE of D‐alpha‐tocopherol daily for 3 months
Trial: 3105472
Drug: cromoglycate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cromoglycate (20 mg)
Trial: 24338893
Drug: Cholesterol-lowering therapy
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering therapy (Pravastatin)
Trial: 22816385
Drug: Okada Purifying
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Okada Purifying Therapy (OPT)